Net Profit Margin
since 2018
Paying user area
Try for free
Moderna Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Total Asset Turnover since 2018
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Moderna Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Moderna Inc., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net income (loss)1 | ÷ | Product sales1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | = | 100 | × | ÷ | |||
| Dec 31, 2022 | = | 100 | × | ÷ | |||
| Dec 31, 2021 | = | 100 | × | ÷ | |||
| Dec 31, 2020 | = | 100 | × | ÷ | |||
| Dec 31, 2019 | = | 100 | × | ÷ | |||
| Dec 31, 2018 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$ in millions
- Net Income (Loss)
- The net income exhibited a negative trend from 2018 through 2020, reflecting increasing losses, with values of -385 million, -514 million, and -747 million US dollars respectively. In 2021, the company reversed this trend and reported a significant net profit of 12,202 million US dollars. However, in 2022, net income decreased but remained positive at 8,362 million US dollars. The latest data point from 2023 shows a sharp decline back to a net loss of 4,714 million US dollars, indicating considerable volatility in profitability over the analyzed period.
- Product Sales
- Product sales data is available from 2020 onward. Starting with 200 million US dollars in 2020, there was a substantial increase to 17,675 million in 2021, followed by a further increase to 18,435 million in 2022. In 2023, sales declined significantly to 6,671 million US dollars, suggesting a possible contraction in revenue after two years of strong growth.
- Net Profit Margin
- The net profit margin similarly demonstrates considerable fluctuations. In 2020, the margin was deeply negative at -373.77%, reflecting the large net loss relative to sales. This metric sharply improved in 2021, reaching a strong positive margin of 69.04%, consistent with the substantial net income reported. In 2022, the margin remained positive but declined to 45.36%, indicating a reduction in profitability relative to sales. By 2023, the margin swung back to negative at -70.66%, underscoring the loss sustained that year relative to revenue.
- Summary of Trends
- Over the period analyzed, the company transitioned from consistent losses in the initial years to a peak profitability phase in 2021, supported by rapid growth in product sales. The following years illustrate a weakening financial performance, with both net income and net profit margins deteriorating markedly in 2023. The substantial decline in sales and profitability in the most recent year indicates potential challenges that may warrant further investigation into operational or market factors affecting performance.
Comparison to Competitors
Moderna Inc., net profit margin, long-term trends, comparison to competitors
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | |||||||||||||
| Dec 31, 2022 | |||||||||||||
| Dec 31, 2021 | |||||||||||||
| Dec 31, 2020 | |||||||||||||
| Dec 31, 2019 | |||||||||||||
| Dec 31, 2018 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Moderna Inc., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Moderna Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2023 | ||
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 31, 2019 | ||
| Dec 31, 2018 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Industry (Health Care)
Moderna Inc., net profit margin, long-term trends, comparison to industry (health care)
| Moderna Inc. | Health Care | |
|---|---|---|
| Dec 31, 2023 | ||
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 31, 2019 | ||
| Dec 31, 2018 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).